July 2020 Cancer Epidemiology Matters E-News
Cancer Epidemiology Matters E-News
- Bolstering Research on Chemical and Physical Exposures and Cancer
- Emergency Resources
- Funding Opportunities
- Grant Policy Notice
- Training Opportunity
- HHS/NIH/NCI News
- NCI Blog Posts
Bolstering Research on Chemical and Physical Exposures and Cancer
Humans are exposed to a wide variety of chemical and physical agents throughout the course of their lives. These agents can have profound effects on human health, including cancer. A growing number of chemical and physical agents have been classified as carcinogens by the National Institute of Environmental Health Sciences’ National Toxicology Program and the World Health Organization’s International Agency for Research on Cancer.
Related Funding Opportunity Announcements
NCI’s Epidemiology and Genomics Research Program (EGRP) is committed to supporting the study of chemical and physical agents and their contribution to cancer risk and occurrence.
For example, EGRP is currently sponsoring two Notices of Special Interests for chemical and physical exposure research, both of which expire on January 8, 2022:
- Use of Biological Information to Understand How the Interplay of Environmental Exposures and Genes Influences Cancer Risk, NOT-CA-20-002, and
- Geospatial Approaches in Cancer Control and Population Sciences, NOT-CA-20-004.
EGRP also intends to publish funding opportunity announcements (FOAs) for new cohorts to assess environmental exposures and cancer risk (see NOT-CA-20-086), and a coordinating center for these cohorts (see NOT-CA-20-091). The estimated publication date for these FOAs is November 1, 2020.
EGRP encourages investigator-initiated grant applications on topics related to chemical and physical exposures. Below is a listing of relevant funding announcements:
- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed), PA-20-185;
- Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional), PAR-18-869;
- Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional), PAR-19-277; and
- NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional), PAR-20-052.
Resources for Adding Environmental Exposures to Existing StudiesNCI-funded investigators who want to add environmental exposures to their studies of human health can also apply for access to laboratory and data analysis services through the Human Health Exposure Analysis Resource (HHEAR) Program. To be considered for the Round 3 review process, applications must be received by August 28, 2020. Learn how to apply at https://hhearprogram.org/how-apply.
In general, application submissions are considered on a rolling basis with about six review cycles per year. For specific dates and deadlines, please visit the HHEAR schedule page at https://hhearprogram.org/hhear-application-submission-and-review-schedule.For more NIH and other resources supporting chemical and physical exposures research, visit EGRP’s Chemical and Physical Exposures webpage.
Connect with EGRP Staff
Those who are planning to attend the International Society of Exposure Science (ISES) 30th Annual Meeting virtually in September 2020 can catch a symposium chaired by EGRP program directors. Somdat Mahabir, Ph.D., M.P.H., and Curt DellaValle, Ph.D., M.P.H. will chair a session titled “Technologies for capture and assessment of environmental exposures implicated in cancer risk.” Speakers include David Donaire-Gonzalez, Ph.D., of the University of Barcelona; EGRP grantee Caroline Johnson, Ph.D., of Yale University; and Perry Hystad, Ph.D., of Oregon State University. This symposium will provide discussion of the use of technologies for the assessment of environmental exposures in diverse populations and geographic areas, with special consideration for application in cancer epidemiology studies.
Questions about research on chemical and physical exposures and cancer can be directed to Curt DellaValle, Ph.D., M.P.H., and Gabriel Lai, Ph.D., program directors in EGRP’s Environmental Epidemiology Branch.
- Phase 3 Clinical Trial of Investigational Vaccine for COVID-19 Begins
- Notice of Special Interest: National Cancer Institute (NCI) Emergency Administrative Supplements for Research and Training Continuity of Postdoctoral Fellows during Coronavirus Disease 2019 (COVID-19) (NOT-CA-20-082)
- Guidance for Applicants Preparing Applications for the Fall 2020 Due Dates During the COVID-19 Pandemic (NOT-OD-20-122)
- NIH-Wide Strategic Plan for COVID-19 Research
- Participant Engagement and Cancer Genome Sequencing (PE-CGS): Research Centers (U2C, Clinical Trial Optional)
- Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01, R21, Clinical Trial Optional)
- Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01, R21, Clinical Trial Not Allowed)
- Biomedical Data Repository (U24, Clinical Trials Not Allowed)
- Development of Biomarkers of Dietary Intake and Exposure (U2C, Clinical Trial Required)*
- Biomarkers of Dietary Intake and Exposure Coordinating Center (U24, Clinical Trial Not Allowed)*
- Ruth L. Kirschstein National Research Service Awards (NRSA):
- Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)
- Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)
- Individual Predoctoral Fellowship (Parent F31)
- Individual Senior Fellowship (Parent F33)
- Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)
- Harnessing Data Science for Health Discovery and Innovation in Africa
* NCI not participating in this funding opportunity
Grant Policy Notice
- Notice of Requirement for Electronic Submission of all Administrative Supplements (NOT-OD-20-128)
NCI Blog Posts
- Study Links Mental Health Treatment to Improved Cancer Survival
- Continuing Our Work in the Time of Two Pandemics
- Childhood Cancer Data Initiative Activities Enhance NCI’s Childhood and AYA Cancer Research
- Ovarian Cancer Studies Aim to Reduce Racial Disparities, Improve Outcomes
- How CRISPR Is Changing Cancer Research and Treatment